Bifonazole--a synopsis of clinical trials worldwide. Status and outlook

A synopsis is given on the results of 97 clinical trials of efficacy and tolerability involving a total of 3,443 patients in more than 20 countries all over the world. They were carried out with bifonazole cream 1%, solution 1%, gel 1% and powder 1%. 49% of the patients treated suffered from dermatophytosis, 30% from cutaneous candidosis and 21% from pityriasis versicolor. The therapeutic efficacy and the tolerability proved good for the indications studied when administered once daily for a treatment period of 2 or 3 weeks.